Page 5 - Heart Failure Guidelines
P. 5

Pediatric Heart Failure Guidelines

                  Medical Management for ARVC ............................................................................................33
                  Follow up for ARVC ...............................................................................................................33
               Chemotherapy Induced Cardiomyopathy ..................................................................................34

                  Additional Evaluation for Patient with Chemotherapy Induced Cardiomyopathy ....................34
                  Medical Management Chemotherapy Induced Cardiomyopathy ............................................34
                  Follow-up Schedule for Chemotherapy Induced Cardiomyopathy ..........................................34
               Neuromuscular Disorder Associated Cardiomyopathy ..............................................................35

                  Additional Evaluation for Patient with Neuromuscular Disorder associated Cardiomyopathy .35
               Introduction ...............................................................................................................................35
               Initial Evaluation ........................................................................................................................35
               Ongoing Management ...............................................................................................................35

                  Dose escalation plan (outpatient monitoring) .........................................................................36
               Imaging .....................................................................................................................................37
               Arrhythmia Screening ................................................................................................................37
               Advanced Therapies .................................................................................................................37
               Myocarditis ................................................................................................................................38
                  Additional Evaluation for possible Myocarditis .......................................................................38
                  Medical Management Myocarditis .........................................................................................38
                  Immunotherapy Management Myocarditis .............................................................................38
                  Follow-up Schedule for Myocarditis .......................................................................................39

               Medication Doses .....................................................................................................................40
               Anticoagulation Schedules ........................................................................................................42




































               Updated 2/11/2019                                                                       page 5
   1   2   3   4   5   6   7   8   9   10